Literature DB >> 28691255

Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery.

Martina A Broglie1, Sandro J Stoeckli1, Rafael Sauter2, Philippe Pasche3, Antoine Reinhard3, Laurence de Leval4, Gerhard F Huber5, Thomas F Pezier5, Alex Soltermann6, Roland Giger7, Andreas Arnold7, Matthias Dettmer8, Andre Arnoux9, Martin Müller9, Stefan Spreitzer10, Florian Lang11, Mathieu Lutchmaya11, Edouard Stauffer12, Vittoria Espeli13, Francesco Martucci14, Massimo Bongiovanni4, Diana Foerbs15, Wolfram Jochum15.   

Abstract

BACKGROUND: Knowledge about prognostic factors in surgically treated patients with oropharyngeal squamous cell carcinoma (SCC) is limited. The purpose of this study was to identify influential factors on survival in a large cohort of patients with surgically treated oropharyngeal SCC.
METHODS: Retrospective analysis of survival estimates in patients with surgically treated oropharyngeal SCC using tumoral positivity for human papillomavirus (HPV) and risk-of-death categories according to a study from 2010 as stratification factors.
RESULTS: The 5-year overall survival (OS) and disease-specific survival (DSS) rates after surgery alone were higher in HPV-associated oropharyngeal SCC (OS 80% vs 62%; P = .01; DSS 92% vs 76%; P = .03). Patients in the low-risk category had higher survival rates (OS 91%; DSS 99%) than patients in the intermediate-risk group (OS 63%; DSS 83%), and high-risk group (OS 61%; DSS 75%).
CONCLUSION: Nonsmokers with HPV-positive oropharyngeal SCC have a better prognosis than smokers with HPV-positive oropharyngeal SCC and also than patients with HPV-negative tumors when treated by surgery alone.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  human papillomavirus; oropharynx; squamous cell cancer; surgery; survival

Mesh:

Year:  2017        PMID: 28691255     DOI: 10.1002/hed.24865

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  SUVmax for predicting regional control in oropharyngeal cancer.

Authors:  Lisa W Lekanne Dit Deprez; Grégoire B Morand; Christian Thüring; Shila Pazahr; Martin W Hüllner; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-15       Impact factor: 2.503

2.  20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes.

Authors:  Stephanie Y Chen; Aisling Last; Abhinav Ettyreddy; Dorina Kallogjeri; Benjamin Wahle; Smrithi Chidambaram; Angela Mazul; Wade Thorstad; Ryan S Jackson; Jose P Zevallos; Patrik Pipkorn
Journal:  Am J Otolaryngol       Date:  2021-01-13       Impact factor: 1.808

3.  Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study.

Authors:  Steve Durante; Vincent Dunet; François Gorostidi; Periklis Mitsakis; Niklaus Schaefer; Judith Delage; John O Prior
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

4.  The impact of human papillomavirus (HPV) status on functional outcomes and quality of life (QOL) after surgical treatment of oropharyngeal carcinoma with free-flap reconstruction.

Authors:  Hani Z Marzouki; Vincent L Biron; Peter T Dziegielewski; Andrew Ma; Jason Vaz; Gabriela Constantinescu; Jeffrey Harris; Daniel O'Connell; Hadi Seikaly
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-09-19

5.  Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer.

Authors:  Yi Rang Kim; Bada Lee; Mi Ran Byun; Jong Kil Lee; Jin Woo Choi
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

6.  Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma.

Authors:  Michaela Plath; Martina A Broglie; Diana Förbs; Sandro J Stoeckli; Wolfram Jochum
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.